The appointment adds seasoned biotech leadership ahead of key Phase 3 data readout for vidofludimus calcium in relapsing MS (expected by end of 2026). No immediate trading catalyst; monitor for any strategic shifts or capital allocation changes under the new Chair.
Price Chart
Executive Summary
Immunic appointed Michael W. Bonney as Chair of the Board, effective May 16, 2026. Bonney brings extensive biopharmaceutical leadership, including roles at Cubist Pharmaceuticals and Biogen, and experience launching MS therapy Avonex. The appointment is a routine board change with no immediate financial impact.
Key Facts
- Michael W. Bonney appointed Chair of the Board effective May 16, 2026.
- Simona Skerjanec transitions from Interim Chair to board member.
- Board size increased from nine to ten members.
- Bonney received an inaugural option grant of 100,000 shares vesting over three years, subject to shareholder approval.
Financial Impact
No material financial impact disclosed. Option grant of 100,000 shares is subject to shareholder approval.
Risk Factors
- Option grant subject to shareholder approval; failure could delay director compensation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193805-26-000645 |
| Document: e665479_ex99-1.htm | 0001193805-26-000645 |
| Document: 0001193805-26-000645-index-headers.html | 0001193805-26-000645 |
| Document: 0001193805-26-000645-index.html | 0001193805-26-000645 |
| Document: 0001193805-26-000645.txt | 0001193805-26-000645 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $12.19 | awaiting T+60 | — | $7.28 (−40.28%) |
Aug 11, 2026 10w ago | 8-K | $15.48 | awaiting T+60 | — | $7.28 (−52.97%) |
Jul 14, 2026 14w ago | 8-K | $14.69 $7.63 | ▼ −48.06% | ▼ −51.44% | $7.28 (−50.44%) |
Jun 29, 2026 17w ago | 8-K | $15.37 $9.37 | ▼ −39.04% | ▼ −42.60% | $7.28 (−52.64%) |
May 19, 2026 22w ago | 3 | $11.55 $16.06 | ▲ +39.05% | ▲ +34.04% | $7.28 (−36.97%) |
May 19, 2026 22w ago | 8-K | $11.60 $16.58 | ▲ +42.93% | ▲ +36.64% | $7.28 (−37.24%) |
Apr 30, 2026 25w ago | S-3/A | $9.65 $13.34 | ▼ −38.24% | ▼ −35.17% | $7.28 (+24.56%) |
Apr 23, 2026 26w ago | 8-K | $9.18 $15.00 | ▲ +63.40% | ▲ +58.38% | $7.28 (−20.70%) |
Apr 14, 2026 27w ago | 8-K | $11.10 $14.77 | ▲ +33.06% | ▲ +24.93% | $7.28 (−34.41%) |
Apr 10, 2026 28w ago | 8-K | $12.20 $14.77 | ▲ +21.07% | ▲ +12.14% | $7.28 (−40.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers